Key result
rAAV2-hIL15 delays tumor onset by ~5 days and prolongs survival in breast cancer mice.
Why the study?
Recombinant AAV2 vectors offer promising gene transfer with low immunogenicity and long-term expression, and IL-15 modulates antitumor activity of immune cells, motivating evaluation of rAAV2-hIL15 for breast cancer immunotherapy.
Does rAAV2-hIL15 vector improve tumor growth and lifespan in a xenograft JC breast cancer mouse model?
Population
Xenograft JC breast cancer model in mice
Comparison
rAAV2-hIL15 vector treatment vs control
Design
Preclinical experimental study
Authors
Loading...
Hypothesis-generating for rAAV2-hIL15 in breast cancer; human translation requires prospective trials.
Does rAAV2-hIL15 vector improve tumor growth and lifespan in a xenograft JC breast cancer mouse model?
Absolute Event Rate: 21% vs 16%
rAAV2-hIL15 shows potential as a therapeutic tool for breast cancer immunotherapy by delaying tumor onset and prolonging survival in a preclinical model.
Yiang (2009) studied Breast cancer (mouse model) (n=18). rAAV2-hIL15 vs. Empty-vector or PBS was evaluated on Time to develop a measurable tumor (days). A single intramuscular injection of rAAV2-hIL15 delayed tumor onset by 5 days (day 21 vs day 16), suppressed tumor growth, and prolonged survival in a mouse model of breast cancer.
Synapse has enriched one closely related paper. Consider it for comparative context: